Observational studyBMC nephrology2026
Kidneys in the crossfire: insights into renal sarcoidosis.
Observational study in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal Sarcoidosis is a rare disease and poorly described. We aimed to characterise the clinical presentation, histopathology, treatment response, and renal outcomes in patients with biopsy proven renal sarcoidosis.
methodsA retrospective observational study with biopsy-proven kidney disease in sarcoidosis, assessing demographics, clinical presentation, histology, treatments, and outcomes. Progression to CKD stage 4/5 or requiring dialysis was the primary outcome. Group comparisons and Cox proportional hazards models were used to identify predictors of the primary outcome.
resultsOf the 32 patients, 44% presented with kidney disease. In others, it was noted 2.5 years after diagnosis of extra-renal sarcoidosis. Granulomatous interstitial nephritis was the most common histology seen (59.4%). Steroids were used in 78.1%, predominantly prednisolone; 56% received high-dose regimen (30 mg/day or more). Over a follow up of 6 years, 9 patients experienced CKD 4/5. Patients who developed primary outcome had significantly lower eGFR at the time of presentation to nephrologist (median 20 vs. 43 mL/min, p = 0.049), and in univariate Cox analysis, younger age at diagnosis was associated with primary outcome (HR 0.95, 95% CI 0.91-1.00; p = 0.039). During follow up, 10 (31%) patients developed relapse, 4 (12.5%) patients progressed to ESKD, and 3 (9%) patients died.
conclusionRenal sarcoidosis is associated with incomplete renal recovery and carries a substantial risk of progression to advanced CKD or ESKD. Younger age and severe renal impairment at presentation were associated with poor renal outcomes, although these findings should be interpreted with caution. Our findings underscore the need for early diagnosis, structured follow-up, and multicentre prospective registries to refine prognostic tools and guide long-term care. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.